Correction to “A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma ( CARAMEL )”

Documenti analoghi

• The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma
  di: Morie A. Gertz
  Pubblicazione: (2024)
• Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma
  di: Samer Al Hadidi, et al.
  Pubblicazione: (2024)
• Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)
  di: Laurent Garderet, et al.
  Pubblicazione: (2024)
• Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta‐analysis
  di: Bruno Almeida Costa, et al.
  Pubblicazione: (2024)
• Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma
  di: Rajshekhar Chakraborty, et al.
  Pubblicazione: (2024)